Dr. Simeone on the Importance of Germline Testing in Pancreatic Cancer

Video

In Partnership With:

Diane M. Simeone, MD, discusses the importance of germline testing in pancreatic cancer.

Diane M. Simeone, MD, Laura and Issac Perlmutter Professor of Surgery in the Department of Surgery; professor in the Department of Pathology; associate director of Translational Research at Perlmutter Cancer Center; professor in the Department of Pathology at NYU Grossman School of Medicine; and director of the Pancreatic Cancer Center of NYU Langone Health, discusses the importance of germline testing in pancreatic cancer.

All patients with pancreatic cancer should receive germline testing, says Simeone. Germline testing helps physicians to identify family members who might be at risk and help said family members undergo the screening they need. Patients should know whether they have family members or parents with pancreatic cancer, or whether they have a family history of pancreatic cancer—especially if it is associated with other cancer types. These patients should seek out a genetic counselor to determine whether or not they should get germline testing and screening done, says Simeone.

For those identified as high risk for pancreatic cancer, annual screening is recommended, along with a pancreatic MRI or magnetic resonance cholangiopancreatography, alternating with an endoscopic ultrasound. That should be done in the setting of a high-risk clinic, where there is a genetic counselor and a team of physicians involved in the patient’s care, concludes Simeone.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD